Literature DB >> 12633912

Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection.

Annie Umbricht1, Donald R Hoover, Marvin J Tucker, Jo M Leslie, Richard E Chaisson, Kenzie L Preston.   

Abstract

With the growing role of intravenous drug use in the transmission of HIV infection, HIV-infected patients frequently present with comorbid opioid dependence. Yet, few empirical evaluations of the efficacy and consequences of opioid detoxification medications in medically ill HIV-infected patients have been reported. In a randomized, double-blind clinical trial, we evaluated the impact of three medications on the signs and symptoms of withdrawal and on the pain severity in heroin-dependent HIV-infected patients (N=55) hospitalized for medical reasons on an inpatient AIDS service. Patients received a 3-day pharmacologic taper with intramuscular buprenorphine (n=21), oral clonidine (n=16), or oral methadone (n=18), followed by a clonidine transdermal patch on the fourth day. Observed and self-reported measures of opioid withdrawal and pain were taken 1-3 times daily for up to 4 days. Opiate administration used as medically indicated for pain was also recorded. Observer- and subject-rated opiate withdrawal scores decreased significantly following the first dose of medication and overall during treatment. Among all 55 subjects, self-reported and observer-reported pain decreased after treatment (on average observer-rated opioid withdrawal scale (OOWS) scores declined 5.6 units and short opioid withdrawal scale (SOWS) declined 4.8 units, P<0.001, for both) with no indication of increased pain during medication taper. There were no significant differences of pain decline and other measures of withdrawal between the three treatment groups. During the intervention period, supplemental opiates were administered as medically indicated for pain to 45% of the patients; only 34% of men versus 62% of women received morphine (P<0.05). These findings suggest buprenorphine, clonidine, and methadone regimens each decrease opioid withdrawal in medically ill HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12633912     DOI: 10.1016/s0376-8716(02)00325-3

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  20 in total

1.  Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.

Authors:  E C Strain; J A Harrison; G E Bigelow
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

2.  Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial.

Authors:  Nat M J Wright; Laura Sheard; Clive E Adams; Bruno J Rushforth; Wendy Harrison; Nicole Bound; Roger Hart; Charlotte N E Tompkins
Journal:  Br J Gen Pract       Date:  2011-12       Impact factor: 5.386

3.  [Withdrawal in a patient with an implantable drug delivery system in spite of continuation of opiate therapy].

Authors:  S Lochner; U Heinrich-Gräfe; W Kirch
Journal:  Internist (Berl)       Date:  2010-05       Impact factor: 0.743

4.  Buprenorphine Initiation and Linkage to Outpatient Buprenorphine do not Reduce Frequency of Injection Opiate Use Following Hospitalization.

Authors:  Phoebe A Cushman; Jane M Liebschutz; Bradley J Anderson; Merredith R Moreau; Michael D Stein
Journal:  J Subst Abuse Treat       Date:  2016-06-11

Review 5.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

6.  Programmable transdermal clonidine delivery through voltage-gated carbon nanotube membranes.

Authors:  Caroline Strasinger; Kalpana S Paudel; Ji Wu; Dana Hammell; Raghotham R Pinninti; Bruce J Hinds; Audra Stinchcomb
Journal:  J Pharm Sci       Date:  2014-05-01       Impact factor: 3.534

7.  Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.

Authors:  Jane M Liebschutz; Denise Crooks; Debra Herman; Bradley Anderson; Judith Tsui; Lidia Z Meshesha; Shernaz Dossabhoy; Michael Stein
Journal:  JAMA Intern Med       Date:  2014-08       Impact factor: 21.873

Review 8.  Methadone at tapered doses for the management of opioid withdrawal.

Authors:  Laura Amato; Marina Davoli; Silvia Minozzi; Eliana Ferroni; Robert Ali; Marica Ferri
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

Review 9.  Pharmacological pain control for human immunodeficiency virus-infected adults with a history of drug dependence.

Authors:  Sanjay Basu; R Douglas Bruce; Declan T Barry; Frederick L Altice
Journal:  J Subst Abuse Treat       Date:  2007-01-09

Review 10.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.